Compass Therapeutics announced that its Phase 2/3 clinical trial results for tovecimig, a bispecific antibody combined with paclitaxel, in advanced biliary tract cancer will be presented orally at the ESMO Congress 2026 in Madrid. The presentation, led by Dr. Nilofer Azad from Johns Hopkins University, will highlight data from the COMPANION-002 trial assessing the drug's effectiveness. This event marks a significant step in showcasing Compass's oncology pipeline and advancing treatment options for this difficult-to-treat cancer. Further details will be shared at the congress in October 2026.
Geely Auto Group reported October vehicle sales of 310,183 units, surpassing 300,000 for the first time in 2026, marking eight consecutive months of year-over-year and month-over-month growth. New energy vehicles (NEVs) accounted for 69% of sales, re...
Atos has appointed Judith Stewart as the new Head of Healthcare & Life Sciences for Asia Pacific, aiming to accelerate growth and innovation in the sector. With over 18 years of healthcare leadership experience, Judith will focus on helping organizat...
Zama has announced its Q3 Shielded report release scheduled for November 2 at 10 a.m. ET. The report will cover the health of its network, adoption of confidential tokens, and developments within its ecosystem of institutions and developers. A discus...
Oil prices fell sharply after US Secretary of State Marco Rubio indicated President Trump prefers a diplomatic resolution to the conflict with Iran rather than military action. Iranian officials also suggested a deal remains possible following talks ...
The total cryptocurrency market capitalization fell by 2.92% to $2.62 trillion as of midnight ET Monday, even though Bitcoin and four out of five other major cryptocurrencies posted gains. Bitcoin rose 0.77% to $78,420, Ether increased 1.17% to $2,29...
